Phase II Trial of Induction Cetuximab (IM-C225), Gemcitabine and Oxaliplatin, Followed by Radiotherapy With Concurrent Capecitabine, and Cetuximab, Followed by Maintenance Cetuximab and Gemcitabine for Patients With Locally Advanced Pancreatic Cancer.

Trial Profile

Phase II Trial of Induction Cetuximab (IM-C225), Gemcitabine and Oxaliplatin, Followed by Radiotherapy With Concurrent Capecitabine, and Cetuximab, Followed by Maintenance Cetuximab and Gemcitabine for Patients With Locally Advanced Pancreatic Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2013

At a glance

  • Drugs Cetuximab (Primary) ; Capecitabine; Gemcitabine; Oxaliplatin
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Mar 2013 Primary endpoint added as reported by ClinicalTrials.gov.
    • 13 Apr 2011 Planned End Date changed from 1 Sep 2011 to 1 Sep 2012, according to ClinicalTrials.gov.
    • 11 Aug 2010 Planned end date changed from 1 Sep 2010 to 1 Sep 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top